18F-FDG PET/CT预测乳腺癌新辅助化疗病理反应的准确性:荟萃分析与系统评价
该系统评价与荟萃分析检索PubMed、Embase、Cochrane Library(Central)和Web of Science(SCI-Expanded),评估18F-FDG PET/CT预测乳腺癌患者新辅助化疗病理反应的准确性。混合效应模型合并的敏感度为81.9%(95%CI 76.0-86.6%),特异度为79.3%(95%CI 72.1-85.1%),诊断比值比为17.35(95%CI 10.98-27.42)。作者结论为18F-FDG PET/CT在新辅助化疗早期预测病理反应具有中等准确性,未来需前瞻性研究探讨化疗方案和不同亚型对葡萄糖代谢水平的影响。
要点
- 18F-FDG PET/CT预测乳腺癌新辅助化疗病理反应的合并敏感度为81.9%(95%CI 76.0-86.6%)。
- 合并特异度为79.3%(95%CI 72.1-85.1%),诊断比值比为17.35(95%CI 10.98-27.42)。
- 病理反应评估同时基于原发肿瘤和淋巴结。
核心结论
- 18F-FDG PET/CT在乳腺癌患者新辅助化疗早期预测病理反应方面具有中等准确性。
研究设计与样本
- 系统评价与荟萃分析,系统检索PubMed、Embase、Cochrane Library(Central)和Web of Science(SCI-Expanded)以纳入相关研究,采用QUADAS-2评估纳入研究的方法学质量,采用Spearman相关系数探讨阈值效应的存在,采用似然比I²指数评估异质性。
诊断标准与关键数值
- 混合效应模型合并的敏感度为81.9%(95%CI 76.0-86.6%),特异度为79.3%(95%CI 72.1-85.1%),诊断比值比为17.35(95%CI 10.98-27.42);病理反应评估同时基于原发肿瘤和淋巴结。
局限性
- 作者指出未来需前瞻性研究探讨化疗方案和不同亚型如何影响葡萄糖代谢水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this meta-analysis was to evaluate the accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients.
METHODS: PubMed, Embase, the Cochrane Library (Central), and the Web of Science (SCI-Expanded) were systematically searched to identify pertinent studies. The methodologic quality of the included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2. The Spearman correlation coefficient was used to explore the existence of a threshold effect. Heterogeneity was assessed by the likelihood ratio I 2 index.
RESULTS: The pooled values calculated with a mixed-effects model for the sensitivity, specificity and diagnostic odds ratio with 95% confidence intervals were 81.9% (76.0-86.6%), 79.3% (72.1-85.1%) and 17.35 (10.98-27.42), respectively.
CONCLUSIONS: 18F-FDG PET/CT has a moderate accuracy in predicting the pathological response during the early process of NAC in breast cancer patients. To increase the role of 18F-FDG PET/CT in monitoring the therapy response, future prospective studies are needed to explore how chemotherapy regimens and different subtypes affect the levels of glucose metabolism.
KEY POINTS: • This meta-analysis assesses the role of PET/CT in breast cancer during NAC. • Pathological responses were based on both primary tumour and lymph node. • 18 F-FDG PET/CT has a moderate accuracy in predicting the pathological response.
引用
- Tian F, Shen G, Deng Y, et al. The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol. 2017. PMID: 28477166. doi:10.1007/s00330-017-4831-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。